Retatrutide vs Semaglutide: Triple vs Single Agonist Comparison

## Semaglutide changed weight loss medicine. Retatrutide might change it again. But which one is right for you right now? That depends on more than just the weight loss numbers -- though the numbers are hard to ignore. Semaglutide (marketed as Ozempic and Wegovy) produces an average of 15% body weight loss. Retatrutide, in its Phase 2 trial, produced 24%. That is a substantial gap, but it does not tell the whole story. This comparison looks at both medications honestly, including factors like availability, safety data, cost, and who benefits most from each. For the tirzepatide perspective, see our [retatrutide vs tirzepatide comparison](/guides/retatrutide-vs-tirzepatide-comparison). For a broader overview of all GLP-1 options, see our [medications comparison chart](/guides/glp1-medications-comparison-chart-guide). Updated March 2026. ## The Core Difference: One Receptor vs Three ### Semaglutide: The Proven Standard Semaglutide activates **GLP-1 receptors only.** This single mechanism produces: - Appetite suppression through hypothalamic signaling - Delayed gastric emptying (you feel full longer) - Improved insulin sensitivity and blood sugar control - Reduced cardiovascular risk (proven in the SELECT trial, Lincoff et al., NEJM 2023) Semaglutide does one thing and does it very well. The [STEP 1 trial](/guides/semaglutide-weight-loss-results-timeline-what-to-expect) (Wilding et al., NEJM 2021) showed 14.9% average weight loss at the 2.4mg dose over 68 weeks, and approximately one-third of participants lost 20% or more. ### Retatrutide: The Triple Threat Retatrutide activates **GLP-1, GIP, and glucagon receptors simultaneously.** This adds: - Everything semaglutide does (via GLP-1) - Enhanced metabolic effects (via GIP, similar to tirzepatide) - **Increased resting energy expenditure** (via glucagon -- unique to retatrutide) - Enhanced hepatic fat oxidation (via glucagon) The Phase 2 trial (Jastreboff et al., NEJM 2023) showed 24.2% average weight loss at 12mg over 48 weeks. For complete titration details, see our [retatrutide dosing protocol guide](/guides/retatrutide-dosing-protocol-complete-titration-guide). Over 50% of participants lost 25% or more of their body weight. ## The Numbers, Side by Side | Metric | Semaglutide (STEP 1) | Retatrutide (Phase 2) | |--------|---------------------|----------------------| | Average max weight loss | 14.9% | 24.2% | | Time to max loss | 68 weeks | 48 weeks (still declining) | | Patients losing 20%+ | ~33% | ~50% | | Mechanism | Reduced intake | Reduced intake + increased burn | | FDA Status | Approved | Investigational | The difference is not subtle. Retatrutide produced roughly 60% more weight loss in 30% less time. The glucagon-mediated increase in energy expenditure appears to be the primary driver of this gap. ### What the Numbers Mean in Real Weight | Starting Weight | Semaglutide (~15%) | Retatrutide (~24%) | Difference | |----------------|-------------------|-------------------|------------| | 200 lbs | 30 lbs lost | 48 lbs lost | 18 lbs | | 250 lbs | 37 lbs lost | 60 lbs lost | 23 lbs | | 300 lbs | 45 lbs lost | 72 lbs lost | 27 lbs | For patients with significant obesity, that extra 20-30 pounds of weight loss can be the difference between remaining in the obese BMI category and reaching an overweight or normal BMI. ## Side Effects: A Surprising Comparison Many patients assume the more powerful drug has worse side effects. The data tells a different story: | Side Effect | Semaglutide | Retatrutide | |-------------|-------------|-------------| | Nausea | 40-45% | 24-35% | | Diarrhea | 25-30% | 15-25% | | Vomiting | 20-25% | 10-15% | | Constipation | 20-25% | 10-20% | | Heart rate increase | Not significant | 5-10 bpm | Retatrutide's nausea rates are actually lower than semaglutide's in their respective trials. For detailed management strategies, see our [retatrutide side effects guide](/guides/retatrutide-side-effects-management-guide) and [semaglutide side effects guide](/guides/semaglutide-side-effects-how-to-manage). The GIP component may buffer some GI effects, similar to what we observe with tirzepatide. See our [semaglutide side effects management guide](/guides/semaglutide-side-effects-how-to-manage) for detailed strategies. The trade-off is a modest heart rate increase from the glucagon component -- typically 5-10 bpm at rest, transient, and clinically insignificant for most patients. **Important caveat:** These numbers come from separate trials with different populations and study designs. Direct comparison requires caution. ## Metabolic Effects Beyond Weight ### Blood Sugar Control - **Semaglutide:** A1C reductions of 1.0-1.5% (extensive diabetes data from SUSTAIN trials) - **Retatrutide:** A1C reductions of 1.5-2.0% in Phase 2 (glucagon may enhance hepatic glucose metabolism) ### Cardiovascular Health - **Semaglutide:** The SELECT trial (2023) proved a 20% reduction in major adverse cardiovascular events. This is a significant advantage -- no other weight loss medication has this level of cardiovascular evidence. - **Retatrutide:** No cardiovascular outcomes data yet. The modest heart rate increase warrants monitoring, though no adverse cardiac events occurred in Phase 2. ### Liver Health - **Semaglutide:** Shows liver fat reduction, but primarily through weight loss and metabolic improvement - **Retatrutide:** May have enhanced liver benefits from glucagon-mediated hepatic fat oxidation -- early data is promising for patients with NAFLD/NASH ## Availability and Access ### Semaglutide -- Widely Accessible - **FDA approved** as Ozempic (diabetes) and Wegovy (weight loss) - **Insurance coverage** possible with prior authorization - **Brand cost:** $935-1,349/month without insurance - **Compounded cost:** $200-400/month (see our [dosing schedule guide](/guides/semaglutide-dosing-schedule-week-by-week-guide)) - **Availability:** Broad -- pharmacies, telehealth platforms, compounding ### Retatrutide -- Limited Access - **Not FDA approved** -- Phase 3 trials ongoing - **No insurance coverage** - **Compounded cost:** $200-650/month depending on dose - **Availability:** Limited to compounding pharmacies with prescriber order - **Expected FDA timeline:** Potentially 2026-2027 ## Who Should Choose Which? ### Semaglutide Is the Better Choice If: - You want an FDA-approved medication with proven long-term safety - Cardiovascular protection matters (SELECT trial data) - You need insurance coverage - Your weight loss goal is 15-20% (achievable with semaglutide alone) - You prefer the most established, well-studied option - This is your first weight loss medication ### Retatrutide Is Worth Considering If: - You have plateaued on semaglutide and need more efficacy - Your weight loss goal exceeds 20% - You have significant obesity (BMI 40+) where the extra efficacy matters most - You are comfortable with an investigational medication - You can access it through a [licensed compounding](/oem) pharmacy -- see our [retatrutide cost guide](/guides/retatrutide-cost-price-guide-2026) for pricing - Your provider has peptide therapy experience - Metabolic rate and fat oxidation are particular concerns ## Practical Switching Considerations ### From Semaglutide to Retatrutide If you and your provider decide to switch (our [switching from semaglutide to tirzepatide guide](/guides/switching-from-semaglutide-to-tirzepatide-complete-guide) covers a similar transition process): 1. Complete your final semaglutide dose 2. Wait 7 days 3. Start retatrutide at 1mg (even if you were on high-dose semaglutide) 4. Follow the standard titration -- your GLP-1 tolerance carries over, but you need time for glucagon adaptation 5. Expect some return of mild GI effects during the transition ### Why Some Patients Stay on Semaglutide Semaglutide is not the "lesser" option. For patients who have lost 15%+ and are maintaining well, switching adds cost, adjustment, and the uncertainty of an investigational drug. Semaglutide also has something retatrutide does not: proven cardiovascular benefit. For patients with cardiac risk factors, that may outweigh the extra weight loss. ## The Bottom Line ### If efficacy is your primary concern: Retatrutide wins 50% more weight loss, faster results, and a mechanism that burns calories rather than just reducing intake. ### If proven safety and access matter most: Semaglutide wins FDA approved, cardioprotective, widely available, and backed by the largest body of clinical evidence in the obesity medication space. ### Our perspective For most patients starting weight loss medication in January 2026, semaglutide remains the practical first choice. It works, it is available, and the safety data is extensive. See our [semaglutide dosing schedule](/guides/semaglutide-dosing-schedule-week-by-week-guide) to get started. But if you have tried semaglutide and hit a wall, or if you have significant weight to lose and maximum efficacy is the priority, retatrutide represents a meaningful step forward -- with the caveat that it remains investigational. We expect this calculus to shift once retatrutide receives FDA approval and Phase 3 data clarifies the long-term safety profile. For a ranked overview of all current options, see our [best weight loss injection 2026 guide](/guides/best-weight-loss-injection-2026-complete-guide). Until then, both are excellent tools when used under proper medical guidance. *Medical disclaimer: Retatrutide is investigational and not FDA approved. Semaglutide is FDA approved as Ozempic and Wegovy. This comparison is educational only. Medication decisions should be made with your healthcare provider based on your individual health profile and goals.* --- ## References - [Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial](https://www.nejm.org/doi/full/10.1056/NEJMoa2301972). *New England Journal of Medicine*, 2023. - [Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)](https://www.nejm.org/doi/full/10.1056/NEJMoa2032183). *New England Journal of Medicine*, 2021. - [Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)](https://www.nature.com/articles/s41591-022-02026-4). *Nature Medicine*, 2022. - [Semaglutide and Cardiovascular Outcomes in Obesity (SELECT trial)](https://www.nejm.org/doi/full/10.1056/NEJMoa2307563). *New England Journal of Medicine*, 2023. - [GIP/GLP-1/Glucagon Triple Agonism: Mechanism and Clinical Potential](https://pubmed.ncbi.nlm.nih.gov/?term=GIP/GLP-1/Glucagon+Triple+Agonism:+Mechanism+and+Clinical). *Nature Reviews Endocrinology*, 2023.